AbbVie (NYSE:ABBV) recently showcased significant advances in oncology, particularly with the introduction of new pipeline ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

AbbVie claims that Genmab turned a blind eye to trade secret theft allegedly used to support the development of ProfoundBio’s ...

Investing in stocks comes with risks. There's no way around that fact. However, some stocks can be less risky than others during certain market conditions. Three Motley Fool contr ...

Genmab denies the accusation that it knowingly stole confidential information in a $1.8 billion deal to acquire a cancer drug ...

The complaint filed in a Seattle court alleges that Genmab, its subsidiary ProfoundBio – which was acquired last year – and ...

As AbbVie accuses Genmab of unlawfully using proprietary ADC technology, find out about their collaboration and the dispute ...

As previously reported, Erste Group upgraded AbbVie (ABBV) to Buy from Hold. The firm notes AbbVie recently confirmed its ...

Eli Lilly and Company, AbbVie, Merck & Co., Inc., Pfizer, D-Wave Quantum, Johnson & Johnson, and Amgen are the seven ...

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options ...

Ross, M.D., Ph.D., vice president, early oncology research and development, AbbVie. "By harnessing the latest scientific breakthroughs in translational research, we are advancing novel therapeutic ...